Influenza, Human: all 2,264 studies

Page 4 of 23. Open to participants first (173), then studies with results posted, then the rest; newest registration first within each.

• Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy AdultsCompletedNCT03814720Phase 1Results posted
• 2017 A/H7N9 IIV RevaccinationCompletedNCT03738241Phase 2Results posted
• Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in ChildrenCompletedNCT03735147Phase 4Results posted
• A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoDActive, not recruitingNCT03734237Phase 4Results posted
• Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCPCompletedNCT03722589Phase 4Results posted
• Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell ResponseCompletedNCT03701061Phase 4Results posted
• Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of AgeCompletedNCT03698279Phase 2Results posted
• Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 YearsCompletedNCT03694392Results posted
• Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza SeasonCompletedNCT03688620Phase 4Results posted
• The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and MetabolomicsTerminatedNCT03686514Phase 4Results posted
• Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe InfluenzaCompletedNCT03684044Phase 3Results posted
• Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian InfluenzaCompletedNCT03682120Phase 2Results posted
• Development of Childhood Anti-Influenza ImmunityCompletedNCT03673345Phase 4Results posted
• Patient Portal - Flu Reminder RecallCompletedNCT03666026Not applicableResults posted
• Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older AdultsTerminatedNCT03658629Phase 2Results posted
• Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like SymptomsCompletedNCT03653364Phase 3Results posted
• Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like SymptomsCompletedNCT03629184Phase 3Results posted
• Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 FormulationsCompletedNCT03617523Phase 4Results posted
• Immunologic Response to Influenza Vaccination in Children and AdolescentsCompletedNCT03614975Phase 4Results posted
• Gene Signatures of Influenza Vaccine Responses in Older AdultsCompletedNCT03603509Phase 4Results posted
• Safety of LAIV4 in Children With AsthmaCompletedNCT03600428Phase 4Results posted
• 2013/2017 H7N9 Prime-Boost IntervalCompletedNCT03589807Phase 2Results posted
• D2560C00015 FluMist Annual Safety Study 2018CompletedNCT03564444Phase 4Results posted
• H3N2 M2SR in Pediatric PopulationCompletedNCT03553940Phase 1Results posted
• Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)CompletedNCT03546192Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A InfectionTerminatedNCT03511066Phase 2Results posted
• Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59CompletedNCT03497845Phase 2Results posted
• Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral InfectionsCompletedNCT03455491Phase 2Results posted
• A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu VaccineCompletedNCT03450915Phase 3Results posted
• Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With InfluenzaCompletedNCT03410862Phase 4Results posted
• Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai AdultsCompletedNCT03390166Phase 2/3Results posted
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing ComplicationsTerminatedNCT03381196Phase 3Results posted
• Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill PatientsCompletedNCT03378479Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A InfectionTerminatedNCT03376321Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable HealthCompletedNCT03339713Phase 2Results posted
• A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated InfluenzaCompletedNCT03336619Phase 3Results posted
• Age and Response to Flu VaccinesTerminatedNCT03328325Phase 4Results posted
• Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy AdultsCompletedNCT03321968Phase 3Results posted
• Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4CompletedNCT03318315Phase 2Results posted
• Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza ACompletedNCT03315104Phase 2Results posted
• Phase 3 Safety and Immunogenicity Study of aQIV in Elderly AdultsCompletedNCT03314662Phase 3Results posted
• Sanofi 2017 H7N9 With/Without AS03 in Adults/ElderlyCompletedNCT03312231Phase 2Results posted
• Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza VaccinesCompletedNCT03308825Phase 4Results posted
• Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in AdultsCompletedNCT03301051Phase 3Results posted
• Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu VaccineCompletedNCT03300050Phase 1Results posted
• Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)CompletedNCT03293498Phase 1/2Results posted
• Flu2Text: Text Message Reminders for 2nd Dose of Influenza VaccineCompletedNCT03287830Not applicableResults posted
• Panblok H7 Vaccine Adjuvanted With AS03 or MF59CompletedNCT03283319Phase 2Results posted
• Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the USCompletedNCT03282240Phase 3Results posted
• Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in EnglandCompletedNCT03278067Results posted
• Flu Vaccine Response in Patients on Biologic TherapiesCompletedNCT03277703Phase 2Results posted
• A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 YearsCompletedNCT03275389Phase 1Results posted
• FluSAFE: Flu SMS Alerts to Freeze ExposureCompletedNCT03274310Not applicableResults posted
• Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 YearsCompletedNCT03233217Phase 1/2Results posted
• Study Examining PrEP-001 in Healthy SubjectsCompletedNCT03220048Phase 2Results posted
• Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy AdultsCompletedNCT03186781Phase 1Results posted
• Efficacy of FLU-v in an H1N1 Influenza Human Challenge ModelCompletedNCT03180801Phase 2Results posted
• Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of AgeCompletedNCT03165617Phase 3Results posted
• Immune Response Following Seasonal Influenza VaccinationCompletedNCT03163342Phase 4Results posted
• Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 SeasonCompletedNCT03158038Phase 4Results posted
• Mood and Influenza Vaccine Response: A Feasibility TrialCompletedNCT03144518Not applicableResults posted
• Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of AgeCompletedNCT03143101Phase 4Results posted
• Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 YearsCompletedNCT03101462Phase 4Results posted
• Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3CompletedNCT03095599Phase 2/3Results posted
• Comparison of Three Licensed Influenza VaccinesCompletedNCT03068949Phase 4Results posted
• Two Doses of Multimeric-001 (M-001) Followed by Influenza VaccineCompletedNCT03058692Phase 2Results posted
• Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza ACompletedNCT03040141Phase 2Results posted
• Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)TerminatedNCT03028987Phase 4Results posted
• Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)CompletedNCT03028974Phase 4Results posted
• Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)TerminatedNCT03023709Phase 4Results posted
• Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)CompletedNCT03023683Phase 4Results posted
• The Human Mucosal Immune Responses to Influenza Virus (SLVP026)CompletedNCT03023553Phase 4Results posted
• T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013CompletedNCT03023176Phase 4Results posted
• T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012CompletedNCT03022435Phase 4Results posted
• T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011CompletedNCT03022422Phase 4Results posted
• T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010CompletedNCT03022396Phase 4Results posted
• B-cell Immunity to Influenza (SLVP017)- Year 5, 2013CompletedNCT03020537Phase 4Results posted
• B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)CompletedNCT03020498Phase 4Results posted
• Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of AgeTerminatedNCT03020472Phase 4Results posted
• Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLUCompletedNCT02998996Phase 1/2Results posted
• Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza ACompletedNCT02989194Phase 2Results posted
• Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV ImmunizationCompletedNCT02987374Phase 4Results posted
• Evaluation of Moderate to Severe Influenza Outcomes in ChildrenCompletedNCT02979626Results posted
• Influenza Vaccine Feasibility Study in Children With Persistent AsthmaCompletedNCT02967393Phase 4Results posted
• A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v VaccineCompletedNCT02962908Phase 2Results posted
• Rapid Diagnostics for Upper Respiratory Infections in the Emergency DepartmentCompletedNCT02957136Not applicableResults posted
• A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With InfluenzaCompletedNCT02954354Phase 3Results posted
• Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza ComplicationsCompletedNCT02949011Phase 3Results posted
• Standard Versus High Dose Inactivated Influenza Vaccine in RACompletedNCT02936180Phase 4Results posted
• Phase 3 Trial of Serbian Seasonal Influenza VaccineCompletedNCT02935192Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With InfluenzaTerminatedNCT02927431Phase 2Results posted
• H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology AnalysesCompletedNCT02921997Phase 2Results posted
• A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu VaccineCompletedNCT02918006Phase 2Results posted
• Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy ChildrenCompletedNCT02915302Phase 4Results posted
• A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.CompletedNCT02914275Phase 3Results posted
• Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 FormulationsCompletedNCT02908269Phase 4Results posted
• Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency DepartmentCompletedNCT02899065Not applicableResults posted
• Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai AdultsCompletedNCT02894840Phase 1/2Results posted
• Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza VaccinesCompletedNCT02893878Results posted
• Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015CompletedNCT02885246Results posted

← Influenza, Human overview